Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Denali Therapeutics Inc. on June 3, 2020. The record date for the meeting was April 13, 2020, with 105,605,386 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
87,977,861 shares (83.31% of outstanding stock) were represented at the meeting. The following matters were approved:
- Proposal 1 (Election of Directors): Three Class III directors were elected to serve until the 2023 annual meeting: David Schenkein, M.D., Jennifer Cook, and Ryan J. Watts, Ph.D.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on executive compensation.
- Proposal 4 (Compensation Vote Frequency): Stockholders approved a one-year frequency for future advisory votes on executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors (David Schenkein, Jennifer Cook, Ryan J. Watts) through the 2023 annual meeting.
- Confirm the engagement of Ernst & Young LLP for the 2020 fiscal year audit.
- Note the shareholder preference for annual advisory votes on executive compensation.
- Review the full Proxy Statement for detailed executive compensation data referenced in Proposal 3.